Clinical Trial Update: Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age [Phase 3]

View source ↗

Summary

Phase 3 immunogenicity and safety study comparing Hib-MenCY-TT (MenHibrix) to PedvaxHIB in healthy infants and toddlers; study completed with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilus Influenzae Type Disease
• Meningococcal Disease Due to Neisseria Meningitidis

Drugs mentioned

• Hib-MenCY-TT (MenHibrix) (Hib-MenCY-TT)
• PedvaxHIB (Haemophilus influenzae type b vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 3 | Status: COMPLETED | Results posted: 2018-06-26